<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862339</url>
  </required_header>
  <id_info>
    <org_study_id>1171</org_study_id>
    <nct_id>NCT03862339</nct_id>
  </id_info>
  <brief_title>The SoundScar Study The SOUNDSCAR Study</brief_title>
  <acronym>SoundScar</acronym>
  <official_title>UltraSOUND-based Characterization of Ventricular Tachycardia SCAR and Arrhythmogenic Substrate; The SOUNDSCAR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Liverpool Heart and Chest Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Non-randomized, Single-arm Study to assess the accuracy of intracardiac&#xD;
      echocardiography (ICE) for characterization of arrhythmogenic substrate in patients with&#xD;
      ischaemic cardiomyopathy undergoing ventricular tachycardia (VT) ablation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICE imaging during VT ablation is currently largely used for definition of cardiac anatomy.&#xD;
      The role of the technique to specifically define scar and arrhythmogenic substrate has not&#xD;
      been systematically evaluated. The aim is to assess the efficacy of the technique to&#xD;
      accurately define the arrhythmogenic substrate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Areas of abnormal contraction (hypokinesia/akinesia) as determined by ICE imaging</measure>
    <time_frame>1 week</time_frame>
    <description>Area with abnormal contraction as correlated the findings on voltage mapping (low voltage) of the left ventricle in patients with a prior myocardial infarction undergoing VT ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areas of abnormal contraction as determined by ICE imaging</measure>
    <time_frame>1 week</time_frame>
    <description>Area of abnormal contraction correlating with the findings on voltage mapping (local abnormal ventricular activities) of the left ventricle in patients with a prior myocardial infarction undergoing VT ablation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischaemic cardiomyopathy undergoing ventricular tachycardia (VT) ablation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior heart attack (myocardial infarction) with evidence from prior non-invasive&#xD;
             imaging demonstrating regions of the heart with reduced heart muscle function&#xD;
             (myocardial hypokinesia/akinesia/thinning) in the absence of a non-heart&#xD;
             attack-related (non-ischaemic) cause&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  One of the following abnormal heart rhythm (VT) events within last 6 months:&#xD;
&#xD;
          -  ≥3 episodes of VT treated with therapeutic rapid pacing from an implantable cardiac&#xD;
             defibrillator (antitachycardia pacing [ATP])&#xD;
&#xD;
          -  ≥1 appropriate shocks from an implantable cardiac defibrillator&#xD;
&#xD;
          -  ≥3 episodes of abnormal heart rhythm (VT) within 24 hours&#xD;
&#xD;
          -  Sustained VT below the detection rate of the implantable cardiac defibrillator&#xD;
             (documented by ECG/cardiac monitor)&#xD;
&#xD;
          -  Sustained abnormal heart rhythm (VT) in the absence of ICD which is documented by&#xD;
             ECG/cardiac monitor&#xD;
&#xD;
          -  Patients in whom ICE imaging is planned for the clinical VT ablation procedure&#xD;
             (clinical indication)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable or unwilling to provide informed consent.&#xD;
&#xD;
          -  Acute heart attack (acute coronary syndrome with acute thrombus diagnosed by coronary&#xD;
             angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible&#xD;
             cause of abnormal heart rhythm (VT) - e.g. electrolyte abnormalities or drug-induced&#xD;
             abnormal heart rhythms&#xD;
&#xD;
          -  Ineligible for ablation (known to have protruding clot in the chamber of interest&#xD;
             (left ventricular thrombus), or have implanted mechanical aortic and mitral valves)&#xD;
&#xD;
          -  Had recent coronary bypass surgery (&lt; 3 months) or percutaneous coronary intervention&#xD;
             (&lt;3 months)&#xD;
&#xD;
          -  Pregnant patients (pregnancy test will be performed in patients who are of&#xD;
             childbearing age who are not on an effective contraceptive prior to all VT ablation&#xD;
             procedures)&#xD;
&#xD;
          -  Had recent coronary bypass surgery (&lt; 3 months) or percutaneous coronary intervention&#xD;
             (&lt;3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saagar Mahida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Heart and Chest Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharad Agarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papworth Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Noorzadeh</last_name>
    <phone>01516001242</phone>
    <email>Michael.Noorzadeh@lhch.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Campbell, BSc</last_name>
      <phone>+61426731727</phone>
      <email>timothy.campbell@sydney.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Mary Wong, PhD</last_name>
      <phone>+61426731727</phone>
      <email>mary.s.wong@sydney.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Saurabh Kumar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Noorzadeh</last_name>
      <email>Michael.Noorzadeh@lhch.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Catheter Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

